20.500.12556/DiRROS-28719 Comparative outcomes of GH treatment in pediatric idiopathic short stature and GH deficiency Context: GH treatment in children with idiopathic short stature (ISS) can be controversial, and analyses comparing responses to children with GH deficiency (GHD) are limited. Objective: To compare the effectiveness and safety of GH treatment in children with ISS and GHD, including those reaching near adult height (NAH). Methods: This post hoc analysis of the NordiNet International Outcome Study (2006-2016) and the American Norditropin Studies: Web-Enabled Research Program (2002-2016) included children with ISS or GHD who initiated treatment aged <18 years. The safety analysis set had birthdate and GH exposure information. The effectiveness analysis set was GH-naïve with valid baseline information. GH exposure, effectiveness, and safety outcomes were analyzed annually for ≤10 years. Results: The safety analysis set included 3816 children with ISS and 22 858 with GHD. The effectiveness analysis set comprised 18 405 children (ISS: 2684; GHD: 15 721), 1856 of whom reached NAH (ISS: 230; GHD: 1626). Average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter. At NAH, height SD score (mean [SD]) was −1.21 (1.09) and −0.90 (1.20) for children with ISS and GHD, respectively, whereas change in height SD score (mean [SD]) from baseline to 10 years was 1.21 (0.86) and 1.45 (1.09). Incidence of adverse reactions was similar across indications, with no new safety signals. Conclusion: GH treatment over 5 to 10 years effectively increased height in children with ISS and children with GHD, including those who reached NAH, with a favorable benefit-risk profile. comparative outcomes growth hormon treatment growth hormon deficiency pediatrics primerjalni rezultati zdravljenje rastnega hormona pomanjkanje rastnega hormona pediatrija true false true Angleški jezik Slovenski jezik Neznano 2026-03-31 09:06:54 2026-03-31 09:06:55 2026-04-01 03:58:37 0000-00-00 00:00:00 2025 0 0 Nasl z nasl. zaslona; Opis vira z dne 31. 3. 2026; str. 1-10 issue 10 Vol. 9 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-053.2 2472-1972 10.1210/jendso/bvaf133 273655811 RAZ_Phillip_Moshe_2025.pdf RAZ_Phillip_Moshe_2025.pdf 1 0A3453D0A80353B2046A17766FB8E5D3 6c29f212b5f18b6f26bb8be441b708da80b536c188e8243410850c8436930188 64c33e50-2cd0-11f1-9147-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=42724 https://academic.oup.com/jes/article/9/10/bvaf133/8236488 1 34a76178-2cd0-11f1-9147-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=42723 Univerzitetni klinični center Ljubljana 0 0 0